Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates

Invasive coronary angiography (ICA) is performed in potential liver transplant (LT) candidates to identify severe coronary artery disease that may either be treated to permit LT or contraindicate LT if untreatable, but its safety and outcomes are not well defined. We show that ICA is associated with a low incidence of complications in LT candidates, although severe coronary artery disease requiring percutaneous treatment followed by dual antiplatelet therapy increased the risk of severe complications. In addition, ICA identifies patients with untreatable disease that can contraindicate LT. Finally, the higher the burden of disease on ICA, the higher the incidence of post-LT cardiovascular events, although this was not associated with increased post-LT mortality. These results support the use of ICA in LT candidates, although being aware of the potential risks is crucial for physicians and patients.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-04-22
DOI
https://doi.org/10.1016/j.jhepr.2025.101428
Citations
2
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
2.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates

Annabel Blasi, Gonzalo Crespo, Roger Pujol, Sergio Rodríguez‐Tajes et al.
2 citations
JHEP Reports
Liver Disease and Transplantation
2.64
article

Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates

Annabel Blasi, Gonzalo Crespo, Roger Pujol, Sergio Rodríguez‐Tajes, Ander Regueiro, Pablo Ruíz, Jordi Colmenero, Giulia Pagano, Salvatore Brugaletta, Carme Ginard, Marta Sánchez-Ric
article en
2 citations

Abstract

Invasive coronary angiography (ICA) is performed in potential liver transplant (LT) candidates to identify severe coronary artery disease that may either be treated to permit LT or contraindicate LT if untreatable, but its safety and outcomes are not well defined. We show that ICA is associated with a low incidence of complications in LT candidates, although severe coronary artery disease requiring percutaneous treatment followed by dual antiplatelet therapy increased the risk of severe complications. In addition, ICA identifies patients with untreatable disease that can contraindicate LT. Finally, the higher the burden of disease on ICA, the higher the incidence of post-LT cardiovascular events, although this was not associated with increased post-LT mortality. These results support the use of ICA in LT candidates, although being aware of the potential risks is crucial for physicians and patients.

JHEP ReportsVol. 7(7)
Hospital Clínic de Barcelona (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universitat de Barcelona (ES)
European Commission, Universitat de Barcelona, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, European Regional Development Fund, European Social Fund
Zero hunger
Openalex Percentile: Top 11%
Liver Disease and Transplantation
2.64
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.